Abstract:Background Osteosarcoma is the most prevalent malignant bone tumour with a poor prognosis. Shikonin (SHK) is derived from the traditional Chinese medicine Lithospermum that has been extensively studied for its notable anti-tumour effects, including for osteosarcoma. However, its application has certain limitations. Valproic acid (VPA) is a histone deacetylase inhibitor (HDACI) that has recently been employed as an adjunctive therapeutic agent that allows chromatin to assume a more relaxed state, thereby enhancing anti-tumour efficacy. Purpose This study was aimed to investigate the synergistic anti-tumour efficacy of SHK in combination with VPA and elucidate its underlying mechanism. Methods/Study Design CCK-8 assays were utilized to calculate the combination index. Additional assays, including colony formation, acridine orange/ethidium bromide double fluorescent staining, and flow cytometry, were employed to evaluate the effects on osteosarcoma cells. Wound healing and transwell assays were utilized to assess cell mobility. RNA sequencing, PCR, and Western blot analyses were conducted to uncover the underlying mechanism. Rescue experiments were performed to validate the mechanism of apoptotic induction. The impact of SHK and VPA combination treatment on primary osteosarcoma cells was also assessed. Finally, in vivo experiments were conducted to validate its anti-tumour effects and mechanism. Results The combination of SHK and VPA synergistically inhibited the proliferation and migration of osteosarcoma cells in vitro and induced apoptosis in these cells. Through a comprehensive analysis involving RNA sequencing, PCR, Western blot, and rescue experiments, we have substantiated our hypothesis that the combination of SHK and VPA induced apoptosis via the ROS-EGR1-Bax axis. Importantly, our in vivo experiments corroborated these findings, demonstrating the potential of the SHK and VPA combination as a promising therapeutic approach for osteosarcoma. Conclusion The combination of SHK and VPA exerted an anti-tumour effect by inducing apoptosis through the ROS-EGR1-Bax pathway. Repurposing the old drug VPA demonstrated its effectiveness as an adjunctive therapeutic agent for SHK, enhancing its anti-tumour efficacy and revealing its potential value. Furthermore, our study expanded the application of natural compounds in the anti-tumour field and overcame some of their limitations through combination therapy. Finally, we enhanced the understanding of the mechanistic pathways linking reactive oxygen species (ROS) accumulation and apoptosis in osteosarcoma cells. Additionally, we elucidated the role of EGR1 in osteosarcoma cells, offering novel strategies and concepts for the treatment of osteosarcoma.

Surfactin induces ER stress‐mediated apoptosis via IRE1‐ASK1‐JNK signaling in human osteosarcoma

Escin induces caspase-dependent apoptosis and autophagy through the ROS/p38 MAPK signalling pathway in human osteosarcoma cells in vitro and in vivo

Molecular Mechanisms of Estrogen Receptor Β-Induced Apoptosis and Autophagy in Tumors: Implication for Treating Osteosarcoma

Synergistic Apoptotic Effect of Crocin and Cisplatin on Osteosarcoma Cells Via Caspase Induced Apoptosis.

CYT997(Lexibulin) induces apoptosis and autophagy through the activation of mutually reinforced ER stress and ROS in osteosarcoma

Water Extract of Sporoderm-Broken Spores of Ganoderma Lucidum Induces Osteosarcoma Apoptosis and Restricts Autophagic Flux

Lycorine Induces Apoptosis and G1 Phase Arrest Through ROS/p38 MAPK Signaling Pathway in Human Osteosarcoma Cells in Vitro and in Vivo

Oxyresveratrol induces apoptosis and inhibits cell viability via inhibition of the STAT3 signaling pathway in Saos‑2 cells

Celastrol Induces Apoptosis and Autophagy Via the ROS/JNK Signaling Pathway in Human Osteosarcoma Cells: an in Vitro and in Vivo Study

Oleanolic acid induces osteosarcoma cell apoptosis by inhibition of Notch signaling.

Inhibition of the Wnt-β-catenin and Notch Signaling Pathways Sensitizes Osteosarcoma Cells to Chemotherapy.

Construction of an ER stress-related prognostic signature for predicting prognosis and screening the effective anti-tumor drug in osteosarcoma

Bioinspired Tumor‐Targeting and Biomarker‐Activatable Cell‐Material Interfacing System Enhances Osteosarcoma Treatment via Biomineralization

Shock wave-induced ATP release from osteosarcoma U2OS cells promotes cellular uptake and cytotoxicity of methotrexate

Shikonin Promotes Adriamycin-Induced Apoptosis by Upregulating Caspase-3 and Caspase-8 in Osteosarcoma

Investigating the Synergy of Shikonin and Valproic Acid in Inducing Apoptosis of Osteosarcoma Cells via ROS-Mediated EGR1 Expression

Ezetimibe inhibits cell viability and invasion by suppressing PI3K/AKT signaling pathway in human osteosarcoma cells

Regulation of Intrinsic and Extrinsic Apoptotic Pathways in Osteosarcoma Cells Following Oleandrin Treatment

The ERK/eIF4F/Bcl-XL Pathway Mediates SGP-2 Induced Osteosarcoma Cells Apoptosis in Vitro and in Vivo

Isoalantolactone inhibits constitutive NF-κB activation and induces reactive oxygen species-mediated apoptosis in osteosarcoma U2OS cells through mitochondrial dysfunction.

Tanshinol suppresses osteosarcoma by specifically inducing apoptosis of U2-OS cells through p53-mediated mechanism